Cas:785777-90-4 5-Bromo-4-(trifluoromethyl)-2(1H)-pyrimidinone manufacturer & supplier

Chemical Name:5-Bromo-4-(trifluoromethyl)-2(1H)-pyrimidinone

CAS.NO:785777-90-4

Synonyms:5-bromo-6-(trifluoromethyl)-1H-pyrimidin-2-one;5-Bromo-4-(trifluoromethyl)-2(1H)-pyrimidinone;2(1H)-Pyrimidinone, 5-bromo-4-(trifluoromethyl)-

Molecular Formula:C₅H₂BrF₃N₂O

Molecular Weight:242.981

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:2.1±0.1 g/cm3

Index of Refraction:1.553

PSA:46.01000

Exact Mass:241.930252

LogP:1.40

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 5-bromo-6-(trifluoromethyl)-1H-pyrimidin-2-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2(1H)-Pyrimidinone, 5-bromo-4-(trifluoromethyl)- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-bromo-6-(trifluoromethyl)-1H-pyrimidin-2-one Use and application,2(1H)-Pyrimidinone, 5-bromo-4-(trifluoromethyl)- technical grade,usp/ep/jp grade.

Related News: Characteristic APIs are usually more complex in structure, and their synthesis involves a variety of technologies such as chiral synthesis, green synthesis, and catalysis, which requires high research and development capabilities in the production process of API companies. 5-Bromo-4-(trifluoromethyl)-2(1H)-pyrimidinone manufacturer Same as Imbruvica’s original monotherapy use, the Venclexta combo offers a convenient oral treatment, while the drug’s two other approved cocktails—with Gazyva or Roche’s Rituxan—involve infusions. 5-Bromo-4-(trifluoromethyl)-2(1H)-pyrimidinone supplier Characteristic APIs are usually more complex in structure, and their synthesis involves a variety of technologies such as chiral synthesis, green synthesis, and catalysis, which requires high research and development capabilities in the production process of API companies. 5-Bromo-4-(trifluoromethyl)-2(1H)-pyrimidinone vendor What’s more, also at the EHA meeting, BeiGene’s Brukinsa showed it could outperform Imbruvica at triggering tumor responses while causing fewer cases of atrial fibrillation, a potentially dangerous heart side effect, in its own head-to-head phase 3 study in previously treated CLL. 5-Bromo-4-(trifluoromethyl)-2(1H)-pyrimidinone factory The United States has suspended imports of dogs from more than 100 countries where there’s a high rabies risk.